Clarivate for Life Sciences & Healthcare’s Post

Our goal at Clarivate is to be the strategic partner to the industry, helping it as it makes some of the most strategic decisions. It was so exciting to see our LatAm team bring together the Life Sciences Industry, across Pharma and Chemical Manufacturers, as well as government and regulators to discuss how we can drive more innovation in Life Sciences in Latin America. Based on those discussions our team, with the help of our customers and partners, created this new whitepaper entitled, LATAM Summit: Navigating market and innovation opportunities. From market development to establishing public policies in LATAM markets, the report discusses how the independence of API imports, internationalization and incremental innovation can impact transformation in the region and shape the future.   Read more on how harmonizing efforts of industry, government and academia can drive effective change, success and innovation in LATAM, here: https://lnkd.in/eg34EyFh   #LATAM #pharma #API #clinicaltrials #innovation

𝐈𝐫𝐞𝐥𝐚𝐧𝐝’𝐬 𝐑𝐨𝐥𝐞 𝐢𝐧 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐒𝐞𝐜𝐭𝐨𝐫 - With over €80 billion in pharmaceutical exports annually, Ireland holds a critical position in the global Health & Life Sciences supply chain—making up 10% of global supply. 🇮🇪💊 This prominent role brings both significant challenges and exciting opportunities for life sciences manufacturers and suppliers. From navigating complex regulations to embracing innovation and sustainability, there’s much to explore. Want to uncover more about the key challenges and opportunities in the industry? Click to learn more: ➡️ https://lnkd.in/eahikNNp

Are you attending CPHI in Milan this year? Don’t miss the upcoming webinar of Clarivate for Life Sciences & Healthcare! It’s a great opportunity to explore the latest trends, challenges, and opportunities in API manufacturing. #API #Manufacturing #CPHI #Milan #Clarivate

The changing dynamics of global API manufacturing - webinar imperdível para quem se preocupa com a cadeia de suprimentos global!

API manufacturing is facing unprecedented challenges and opportunities, from increasing regulatory scrutiny to rising costs and intensified competition, the industry is in a state of flux. Join the upcoming webinar with - Molly Bowman, Head of Strategy for Pharmaceutical SCM, Clarivate Analytics, Mike Ward, Head of Thought Leadership, Life Sciences, Clarivate Analytics, Alicia Xaka, Associate Director, Business Development, US & Canada, PROCOS S.P.A. (CBC Group) and Gunjan Singh, Head of Mature Markets API, Dr. Reddy's Laboratories - to explore the evolving landscape of API manufacturing, major industry changes in Chinese and Indian markets, navigating competitive pressures and more. Register here: https://lnkd.in/e-GBensb #RegulatoryCompliance #APIManufacturing #Pharma #Webinar #IndustryInsights

Pharma production is forecast to experience healthy growth over the coming years 🧪📈 The main growth drivers are aging populations, emerging markets demand and new products, but some concerns around profitability exist 🤔 In the US and Europe, governments are pushing back against high drug costs with new pricing policies, which could limit revenues and lower incentives to invest in R&D. In emerging markets, quality standard issues remain a downside risk. Read about the latest developments and trends in the industry provided by our pharmaceutical sector experts 👉 https://brnw.ch/21wMw8p ✍️ Judy Ji ✍️ Rubén Del Río Hernández ✍️ Brady McKinney ✍️ Christian Bürger #pharmaceuticals #pharmaindustry #pharmaoutlook #pharceuticalsindustry #pharceuticalsoutlook

The recently published 'Draghi report' (The future of European competitiveness) requested by the European Commission, emphasizes the geostrategic significance of the Pharma sector in Europe and identifies the competitiveness gap as a critical issue for the sector, particularly due to the following reasons: • Lesser and fragmented public R&D investment in the EU. • Lesser private R&D investment in the EU and a weaker supporting environment. • A slow and complex EU regulatory framework. • The complex emergence of a European Health Data Space (EHDS-Koalition). This may become the most significant challenge for the Pharma industry in Europe in the upcoming years, and to address this issue effectively, the report suggests additional reforms and proposes a range of measures such as: - Maximise the impact of the EU Health Data Space - Streamline the set-up and management of multi-country trials in the EU - Expedite access to markets through coordinated action - Provide clear and timely guidance on the use of AI - Increase and focus public R&D investment in the EU as well as mobilise private R&D investment - Develop strategic international partnerships After reading the report, it is clear that both public institutions financial support and public-private partnerships are crucial for economic progress and competitiveness, particularly in vital industries like pharmaceuticals.

When R&D giants sneeze, clinical trials suffer.  It’s a well-known fact that the #Pharma sector is among the most R&D intensive industries in the world, with massive investments in #Innovation. Based on quarterly reporting, however, we can see an overall drop in R&D spending between the first halves of 2023 and 2024 (with some companies hit harder than others). As a result, clinical trials are also declining, particularly in European countries.  Key findings: 🚨 12.9% global decrease in R&D spending 🚨 Overall decline in all countries, including: 30.9% decrease in EU5 region 22.9% decrease in Canada. Reasons behind this decline in R&D go beyond cyclical investment trades. They also include more systemic issues, likely influenced by national policy decisions impacting the pharmaceutical sector. Countries and patients should take note of these issues to right the ship.  #Research #ClinicalTrials #Pfizer #JnJ #Abbvie #Merck #Sanofi #Roche #GSK #AstraZeneca #Novartis #BMS Gabin Nathan

🚀 Unlocking the secrets of R&D #efficiency, #effectiveness and #productivity in #Pharma! 🧪 𝙍&𝘿 𝙚𝙛𝙛𝙞𝙘𝙞𝙚𝙣𝙘𝙮: it’s all about translating ideas, effort, and investment into tangible results. Some companies are nailing it with a cost-per-approval as low as $1.7 billion, while others… well, let’s just say they’re hitting the other extreme at $6.9 billion! R&D efficiency is highly variable between companies, with the median cost per new product approval at $2.8 billion. 𝙍&𝘿 𝙚𝙛𝙛𝙚𝙘𝙩𝙞𝙫𝙚𝙣𝙚𝙨𝙨: Not just about getting products across the finish line, but delivering real value. The median company NPV per approval was $5.4 billion. External factors such as IRA in the US and anticipated reductions in regulatory exclusivity in the EU are already impacting R&D strategic decisions on projects' investment and progression. There is an expectation that R&D portfolios will be gradually refocused on biologics that are less vulnerable to value erosion. Strong commercial forecasting and execution capabilities are also key levers to improve companies performance. #RnDEfficiency #RnDEffectiveness #RnDproductivity #pharmainnovation #biotechinnovation #biopharmainnovation #healthcareinnovation #pharmatrends #pharmaRnD #drugdevelopment https://lnkd.in/dBh4v9iX.

On October 14th, the Healthcare Team, led by Justine Bennett, alongside associates Eric Bagdasarian and Daniel Moya initiated an investment into Bruker Corporation, Inc. (BRKR). BRKR is a leading supplier of high-end analytical scientific instruments to end markets in pharmaceutical, clinical and chemical materials industries. Weakness in BRKR’s end markets resulted in negative sentiment for BRKR, alongside a top-line miss in its 1Q’24 earnings. However, despite transitory weakness within pharmaceutical end markets, BRKR sported industry-leading organic growth, driven by its positioning within sustainable end markets such as industrial and academic end markets. Moving forward, BRKR’s inorganic growth strategy and investments in its product line supported its ongoing portfolio evolution into high-growth areas. The team sees shares reaching $86 over the next 12-18 months, providing 28.4% upside.